Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.

Narwal R, Roskos LK, Robbie GJ.

Clin Pharmacokinet. 2013 Nov;52(11):1017-27. doi: 10.1007/s40262-013-0085-2.

2.

Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.

Zheng B, Yu XQ, Greth W, Robbie GJ.

Br J Clin Pharmacol. 2016 May;81(5):918-28. doi: 10.1111/bcp.12864. Epub 2016 Mar 4.

PMID:
26659791
3.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

PMID:
21798883
4.

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W.

Arthritis Rheum. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824.

6.

A guide to rational dosing of monoclonal antibodies.

Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ.

Clin Pharmacokinet. 2012 Feb 1;51(2):119-35. doi: 10.2165/11596370-000000000-00000.

PMID:
22257150
7.

Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.

Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, Hsu B, Pendley C, Wagner C, Davis HM, Zhou H.

Int J Clin Pharmacol Ther. 2010 Sep;48(9):596-607.

PMID:
20860913
8.

Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C.

Clin Pharmacokinet. 2009;48(7):477-87. doi: 10.2165/11313400-000000000-00000.

PMID:
19691369
9.

Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.

Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ.

Clin Pharmacokinet. 2012 Apr 1;51(4):247-60. doi: 10.2165/11598090-000000000-00000.

PMID:
22420579
10.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE.

J Clin Pharmacol. 2007 Mar;47(3):383-96.

PMID:
17322150
11.

Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ.

Clin Pharmacokinet. 2011 Dec 1;50(12):793-807. doi: 10.2165/11594240-000000000-00000.

PMID:
22087866
12.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
13.

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.

Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D.

Pharm Res. 2006 Jun;23(6):1275-84. Epub 2006 May 26.

PMID:
16715358
14.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
15.

Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.

Chen P, Vu T, Narayanan A, Sohn W, Wang J, Boedigheimer M, Welcher AA, Sullivan B, Martin DA, Ruixo JJ, Ma P.

Pharm Res. 2015 Feb;32(2):640-53. doi: 10.1007/s11095-014-1492-2. Epub 2014 Sep 12.

PMID:
25213774
16.

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B.

Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14.

PMID:
25119184
17.
18.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.

Clin Ther. 2011 Jul;33(7):946-64. doi: 10.1016/j.clinthera.2011.06.002. Epub 2011 Jul 7.

PMID:
21741088
19.

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J.

Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19.

PMID:
18205003
20.

Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.

Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R.

Clin Pharmacokinet. 2014 Jul;53(7):637-48. doi: 10.1007/s40262-014-0143-4.

PMID:
24756395
Items per page

Supplemental Content

Write to the Help Desk